The first TelehealthONE kiosk was launched at a Fred’s location in Flora, Miss. in September 2015, and the next nine will hit the communities of Union, Pelahatchie, Carthage, Morton, Jackson, Pearl, Clinton, Lexington and Terry.
Afferent is a leader in developing therapeutic candidates to treat common, poorly managed neurogenic conditions by targeting the P2X3 receptor, and its lead candidate, AF-219, is currently being evaluated in clinical trials to treat refractory, chronic cough, as well as idiopathic pulmonary fibrosis with cough.
Kinney Drugs was recently recognized for its patient medication adherence performance in 2015. According to North Country Now, the recognition is part of the performance program by CVS Caremark, the prescription benefit management business of CVS Health that focuses on driving improvements in medication safety and adherence and improving health outcomes of each patient. (North Country Now).
The report also notes that rising healthcare costs and lack of access to primary care are part of what’s driving this growth, as well as rising premiums and higher deductibles among patients with health insurance.
According to a review of more than 11,000 websites selling prescription medication to U.S. consumers, about 96% are out of compliance with U.S., laws and 50% of the medication sold are fake or counterfeit.
Drug Store News recently caught up with Doyle Jensen, EVP global business development at pharmacy automation company Innovation to talk about the company's offerings for pharmacies looking to move toward a high-volume central-fill solution and the future of pharmacy automation.
Under the partnership, Ultragenyx will initially receive an exclusive license for one of Takeda’s preclinical product candidates in a pre-determined field of use, along with the option to co-develop and co-commercialize the candidate in other therapeutic areas.
WellCare Kentucky — a subsidiary of WellCare Health Plans — is making 1,000 twist-on naloxone nasal atomizers available for free, and pharmacists will provide them to Medicaid recipients and patients who don’t have insurance without a prescription.
In a new report, the IMS Institute for Healthcare Informatics examines the growth in the oncology market in 2015 while looking forward to 2020 and examining the ways new cancer treatments are changing the healthcare landscape in terms of cost and distribution.
Mylan on Thursday launched two new generic products. The company rolled out its generic of Celgene’s Vidaza (azacitidine, 100 mg/vial) injection and its generic of GSK’s Rhythmol (propafenone HCl) extended-release capsules.